Minerva Neurosciences, Inc. (NERV) Reaches $8.40 After 8.00% Down Move; 3D Systems (DDD) Sellers Decreased By 0.76% Their Shorts




June 6, 2018 – By David Stenberg

3D Systems Corporation (NYSE:DDD) had a decrease of 0.76% in short interest. DDD’s SI was 35.36M shares in June as released by FINRA. Its down 0.76% from 35.63 million shares previously. With 2.26 million avg volume, 16 days are for 3D Systems Corporation (NYSE:DDD)’s short sellers to cover DDD’s short positions. The SI to 3D Systems Corporation’s float is 32.28%. The stock decreased 0.75% or $0.105 during the last trading session, reaching $13.985. About 2.65 million shares traded. 3D Systems Corporation (NYSE:DDD) has declined 46.74% since June 6, 2017 and is downtrending. It has underperformed by 59.31% the S&P500. Some Historical DDD News: ; 14/03/2018 – 3D SYSTEMS 4Q GROSS MARGIN +48.2%, EST. +47.9%; 14/03/2018 – 3D SYSTEMS 4Q REV. $177.3M; 21/05/2018 – 3D Systems’ NextDent™ 5100 Named 2018 Healthcare Application of the Year by Additive Manufacturing Publication ‘3D Printing I; 16/03/2018 – 3D SYSTEMS CORP DDD.N : DEUTSCHE BANK RAISES TARGET PRICE TO $13 FROM $9; 21/05/2018 – 3D Systems’ NextDent™ 5100 Named 2018 Healthcare Application of the Year by Additive Manufacturing Publication ‘3D Printing Industry’; 02/04/2018 – 3D Systems Delivering on Prototyping to Production Promise – Highlighting Customer Applications at AMUG 2018; 26/04/2018 – 3D Systems’ Figure 4™ 3D Printing Platform Selected for U.S. Air Force Research into Rapid Part Replacement; 23/04/2018 – 3D Systems Moves Manufacturers from Prototyping to Production – Showcasing New Solutions at RAPID+TCT 2018, Including Figure 4; 13/04/2018 – 3D Systems Prevails in Accounting Trial for Former Employee’s Violation of Non-Competition Covenant; Court Orders Disgorgement; 06/03/2018 Onkos Surgical® and 3D Systems Team to Advance Personalized Surgical Oncology Solutions

The stock of Minerva Neurosciences, Inc. (NASDAQ:NERV) is a huge mover today! The stock decreased 2.33% or $0.2 during the last trading session, reaching $8.4. About 153,799 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has risen 15.03% since June 6, 2017 and is uptrending. It has outperformed by 2.46% the S&P500. Some Historical NERV News: ; 17/05/2018 – Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp; 26/04/2018 – Minerva Surgical Requests Immediate Retraction of Misleading Int’l Journal of Women’s Health Publication that Compares NovaSure; 17/05/2018 – Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia; 19/03/2018 – MINERVA LUXEMBOURG S.A. ANNOUNCES THAT HSBC SECURITIES (USA) INC. HAS LAUNCHED A TENDER OFFER, AND MINERVA LUXEMBOURG S.A. HAS LAUNCHED A CONSENT SOLICITATION, RELATING TO ANY AND ALL OF THE 8.750%…; 19/04/2018 – DJ Minerva Neurosciences Inc, Inst Holders, 1Q 2018 (NERV); 17/05/2018 – MINERVA REPORTS COGNITIVE IMPROVEMENTS WITH ROLUPERIDONE; 04/04/2018 – MINERVA LUXEMBOURG S.A. ANNOUNCES THAT HSBC SECURITIES (USA) INC. HAS EXTENDED THE EARLY TENDER DATE RELATING TO THE TENDER OFFER FOR ANY AND ALL OF THE 8.750% PERPETUAL NOTES ISSUED BY MINERVA…; 03/05/2018 – MINERVA NEUROSCIENCES INC – CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE ABOUT $121.1 MLN; 06/03/2018 – MINERVA CEO: BRF CASE DIDN’T HAVE EFFECT ON EXPORTS; 09/05/2018 – MINERVA BOARD NAMES IBAR VILELA DE QUEIROZ CHAIRMANThe move comes after 7 months negative chart setup for the $325.49 million company. It was reported on Jun, 6 by Barchart.com. We have $7.73 PT which if reached, will make NASDAQ:NERV worth $26.04M less.

Another recent and important 3D Systems Corporation (NYSE:DDD) news was published by Seekingalpha.com which published an article titled: “3D Systems: Buy This Industry Disruptor” on June 06, 2018.

Investors sentiment increased to 1.17 in Q1 2018. Its up 0.18, from 0.99 in 2017Q4. It increased, as 13 investors sold 3D Systems Corporation shares while 58 reduced holdings. 33 funds opened positions while 50 raised stakes. 72.83 million shares or 1.60% more from 71.68 million shares in 2017Q4 were reported. Teacher Retirement System Of Texas owns 23,946 shares. Morgan Stanley reported 0% of its portfolio in 3D Systems Corporation (NYSE:DDD). Stratos Wealth Ptnrs Ltd stated it has 0% of its portfolio in 3D Systems Corporation (NYSE:DDD). Legal And General Group Inc Public Limited Com reported 1.22M shares stake. The Ohio-based Fifth Third Bancshares has invested 0% in 3D Systems Corporation (NYSE:DDD). Cibc Markets Incorporated holds 26,036 shares or 0% of its portfolio. Bluecrest Limited has invested 0.01% in 3D Systems Corporation (NYSE:DDD). Focused Wealth Management reported 30 shares stake. Proshare Ltd Limited Liability Company stated it has 0% in 3D Systems Corporation (NYSE:DDD). 35,101 were accumulated by Creative Planning. Oz Lp holds 0.06% in 3D Systems Corporation (NYSE:DDD) or 850,200 shares. Synovus reported 382 shares stake. Advantus Cap Mngmt owns 13,924 shares. Texas Permanent School Fund has 75,378 shares for 0.01% of their portfolio. North Carolina-based Salem Counselors Incorporated has invested 0% in 3D Systems Corporation (NYSE:DDD).

Among 19 analysts covering 3D Systems Corporation (NYSE:DDD), 2 have Buy rating, 6 Sell and 11 Hold. Therefore 11% are positive. 3D Systems Corporation had 68 analyst reports since July 22, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, July 29 by Longbow. The firm earned “Buy” rating on Wednesday, December 30 by Needham. Bank of America downgraded the shares of DDD in report on Wednesday, November 1 to “Underperform” rating. The stock has “Buy” rating by Gabelli on Wednesday, November 1. The firm has “Overweight” rating given on Thursday, December 17 by Stephens. The firm earned “Buy” rating on Thursday, April 14 by Bank of America. The company was maintained on Monday, August 10 by Pacific Crest. The firm earned “Underweight” rating on Tuesday, July 4 by Piper Jaffray. The firm has “Neutral” rating given on Wednesday, November 1 by JP Morgan. The firm earned “Hold” rating on Monday, November 20 by Piper Jaffray.

3D Systems Corporation, through its subsidiaries, provides 3D printing services and products worldwide. The company has market cap of $1.59 billion. The companyÂ’s 3D printers transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts using a range of print materials, including plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and Class IV bio-compatible materials. It currently has negative earnings. It offers various 3D printing technologies, such as stereolithography, selective laser sintering, direct metal printing, multijet printing, and colorjet printing.

Since May 7, 2018, it had 2 insider buys, and 0 insider sales for $220,997 activity. LOEWENBAUM G WALTER II bought $54,270 worth of stock or 4,500 shares.

Analysts await Minerva Neurosciences, Inc. (NASDAQ:NERV) to report earnings on August, 2. They expect $-0.35 EPS, down 29.63% or $0.08 from last year’s $-0.27 per share. After $-0.32 actual EPS reported by Minerva Neurosciences, Inc. for the previous quarter, Wall Street now forecasts 9.37% negative EPS growth.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company has market cap of $325.49 million. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It currently has negative earnings. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder.

3D Systems Corporation (NYSE:DDD) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


By1 David Stenberg



Source link

Leave a Reply